Results 101 to 110 of about 22,516 (228)
AR staining profiles of normal prostate, primary PCa and CRPC.
, 2013 (A) IHC staining for N- and C-terminal AR in normal prostate (NP) (a and b), hyperplastic prostate (HP) (c and d) and primary PCa (e-h) (magnification x200).
Colm Morrissey (35516) +8 more
core +1 more source
Role of Androgen Receptor in Prostate Cancer: A Review
The World Journal of Men's Health, 2019 Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding domain, hinge region, and ligand-binding domain.
Kazutoshi Fujita, Norio Nonomura
doaj +1 more source
RSK1-driven TRIM28/E2F1 feedback loop promotes castration-resistant prostate cancer progression
The Journal of Clinical InvestigationCastration-resistant prostate cancer (CRPC) marks the advanced and lethal stage of prostate cancer (PCa). TRIM28, also known as KAP1, is a transcriptional regulator recently shown to promote CRPC cell proliferation and xenograft tumor growth. Nonetheless,
Miyeong Kim +10 more
doaj +1 more source
Frontiers in ImmunologyBackgroundProstate cancer (PCa) is a common malignant tumor in males, and castration-resistant prostate cancer (CRPC) represents an advanced stage with limited treatment options and poor prognosis.
Sixin Li +13 more
doaj +1 more source
PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer
Cell Death and DiseaseCastration-resistant prostate cancer (CRPC) is the advanced stage of prostate cancer (PCa) progression, characterized by limited therapeutic options and significant challenges from drug resistance development.
Lin Chen +11 more
doaj +1 more source
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer
The Journal of Clinical InvestigationMediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC).
Jing Li +25 more
doaj +1 more source
Targeting AURKA with multifunctional nanoparticles in CRPC therapy
Journal of NanobiotechnologyCastration-resistant prostate cancer (CRPC) presents significant therapeutic challenges due to its aggressive nature and poor prognosis. Targeting Aurora-A kinase (AURKA) has shown promise in cancer treatment. This study investigates the efficacy of ART-T cell membrane-encapsulated AMS@AD (CM-AMS@AD) nanoparticles (NPs) in a photothermal-chemotherapy ...
Bin Deng +5 more
openaire +3 more sources
Actualité de la Mission: la CRPC
, 2015 Suite à l’appel à projets sur la Comparution sur Reconnaissance Préalable de Culpabilité (CRPC) lancé par la Mission de recherche Droit et Justice dans le cadre de sa programmation 2015, le projet présenté par les professeurs Jérôme Bossan, Cristina ...
mrdj
core
Clinical and Preclinical Treatment Aspects of Castration Resistant Prostate Cancer (CRPC) [PDF]
, 2012 In the Western countries prostate cancer is the most frequently diagnosed cancer, except for skin cancer, and the second leading cause of male cancer deaths.
Meulenbeld, H.J. (Hielke)
core
The association of JAK2 polymorphisms with prognosis in castration-resistant prostate cancer (CRPC).
, 2016 313 Background: We evaluated variation in candidate genes implicated in either initiation or progression of prostate cancer with survival in CRPC stage.
Shaun M. Riska +8 more
core +1 more source